SCHEMBL4753292

SCHEMBL4753292

Cc1cccc(CCCOC(C)C2CN(C(=O)c3cccnc3Cl)CCN2C(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.39
PPARG P37231 2/20 0.34
MGLL Q99685 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
FAAH O00519 1/20 0.32
HCRTR1 O43613 2/20 0.32
HCRTR2 O43614 2/20 0.32
ALDH1A1 P00352 1/20 0.32
PIK3CG P48736 1/20 0.32
HSD11B1 P28845 1/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753294 0.83 CYP2C19 (0.43) CYP2C19POLBPPARGMGLLGABRA1
SCHEMBL4750792 0.76 POLB (0.52) CYP2C19POLBPPARGGABRA1GABRG2
SCHEMBL4750996 0.65 ALDH1A1 (0.45) CYP2C19POLBLMNAMAPTALDH1A1
SCHEMBL1976542 0.64 POLB (0.65) CYP2C19POLBLMNAMAPTTHRB
SCHEMBL4751021 0.64 SMN1; SMN2 (0.38) CYP2C19POLBPPARGLMNAMAPT
SCHEMBL1863115 0.62 POLB (0.63) CYP2C19POLBLMNAMAPTALDH1A1
SCHEMBL8408752 0.62 KCNH2 (0.40) POLBPPARGGABRA1GABRG2GABRB3
SCHEMBL4753160 0.60 ALDH1A1 (0.50) LMNAALDH1A1KMT2AMEN1MAPK1
SCHEMBL4753119 0.60 GRM5 (0.42) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL4753349 0.59 ALDH1A1 (0.47) POLBLMNAMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO disclosed